British-Swedish drugmaker AstraZeneca has obtained orphan drug designation from the US Food and Drug Administration (FDA) for its anti-CTLA-4 monoclonal antibody, tremelimumab to treat malignant mesothelioma.
Mesothelioma is a rare and aggressive cancer that affects the lining of the lungs and abdomen, and limited treatments are available for this cancer.
Tremelimuma is a fully human monoclonal antibody that stimulates the immune system to destroy cancer cells through binding to the protein CTLA-4, expressed on the surface of activated T-lymphocytes.
AstraZeneca global medicines development and immuno-oncology head and senior vice-president Robert Iannone said: “There is a significant need for new treatment options for patients with mesothelioma because fewer than 5% of patients currently survive beyond five years, even when they receive timely diagnosis and care.
“Our aim is to rapidly advance the development of tremelimumab as a potential new treatment option for these patients.”
Along with its biologics research and development arm MedImmune, AstraZeneca has developed tremelimumab. It is part of the broad pipeline of immuno-oncology assets being developed by both firms to harness the body’s own immune system to fight cancer.
How well do you really know your competitors?
Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.
Thank you!
Your download email will arrive shortly
Not ready to buy yet? Download a free sample
We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form
By GlobalDataTremelimumab is currently being studied in combination with AstraZeneca’s anti PD-L1 investigational immunotherapy MEDI4736 in tumour types, including non-small cell lung cancer and head and neck cancer.
In addition, it is being studied in combination with Iressa (gefitinib) in EGFR mutated non-small cell lung cancer and with MEDI6469 (a murine OX40 agonist) in solid tumours.
Image: Micrographs showing mesothelioma in a core biopsy. Photo: courtesy of Robertolyra.